The disease groups that make up the OneOncology clinical pathways program cover 90% of patients with cancer and develop best practices for treating cancer in the majority of patients, said Edward “Ted” Arrowsmith, MD, MPH, managing partner and director of research, East Tennessee Division, Tennessee Oncology.
The disease groups that make up the OneOncology clinical pathways program cover 90% of patients with cancer and develop best practices for treating cancer in the majority of patients, said Edward “Ted” Arrowsmith, MD, MPH, managing partner and director of research, East Tennessee Division, Tennessee Oncology.
Transcript
What is the role of disease groups in the OneOncology clinical pathways program?
Our idea of pathways is to have them really be bottom up and then top down. We've instituted disease groups that cover about 90% of patients with cancer. They have experts from each of the 15 practices in OneOncology, and work collaboratively to develop the pathways to develop best practices for treatment of cancer for the majority of patients. Of course, there'll be some patients who being off pathway is the right thing to do, but this is the expert consensus. It then comes up to the clinical team at OneOncology, who does clerical work and other work, and then helps push that information back to every doctor practicing across the practices in OneOncology.
How do member practices of OneOncology work with these clinical pathways day to day? How will the OneOncology annual conference help practices learn more about working with pathways?
Our pathways process is relatively new. OneOncology is a new organization, and we've been working on pathways really diligently for about 18 months. The main way that we see providers working with the pathways will be through a tool called Flatiron Assist. And the OneOncology conference this weekend is the big kind of rollout of that tool. That's a clinical decision support tool developed in conjunction with Flatiron Health who's our EMR [electronic medical record] partner. Based on the intellectual work done by the disease groups [the tool] will guide clinicians to using a pathway concordant regimen, whenever they order. That can be customized by OneOncology based on value-based care, clinical trials, or other attributes that are unique to our practices.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen